Global Orthopedic Regenerative Surgical Products Market (2022 to 2030) – Size, Share and Trend Analysis Report

DUBLIN, April 19, 2022–(BUSINESS WIRE)–The “Orthopedic Regenerative Surgical Products Market Size, Share, and Trend Analysis Report by Product (Allograft, Synthetic, Cell-based, Viscosupplements), by Application, by end-use, by region and segment forecast, report 2022-2030″ has been added to from offer.

The global orthopedic regenerative surgical products market size is expected to reach USD 5.6 billion by 2030. The market is expected to grow at a notable CAGR of 3.9% from 2022 to 2030.

Companies cited

  • Baxter

  • Zimmer Biomet

  • stryker

  • Smith+Nephew

  • Allosource

  • Amniox Medical, Inc.

  • Anika Therapeutics, Inc.

  • Vericel Corporation

  • Vsy Biotechnologie GmbH

  • Aptissen SA

  • mimedx

Major factors driving the growth of the market include increasing geriatric population, orthopedic procedures, research activities, and technological advancements. Osteoarthritis, for example, has been identified as the leading cause of chronic disability in the geriatric population over the age of 70. The World Health Organization (WHO) has also designated osteoarthritis as a “priority disease” encouraging R&D for therapies to treat osteoarthritis and its associated symptoms.

Market growth has been stunted during the COVID-19 pandemic due to delayed elective surgeries, low volume of patient flow for chronic diseases in clinics and hospitals, decrease in sales and marketing activities, quarantine and lockdown protocols and low demand. Vericel Corporation, for example, reported the negative impact of COVID-19 on its business and operations in 2020. The company recorded planned MACI procedure cancellations; its flagship product used in the repair of cartilage lesions of the knee. Additionally, there has been a slowdown in new orders. Anika Therapeutics has reported difficulty recruiting patients for its clinical trials due to the pandemic, which has negatively impacted the company’s revenue and operating results. However, both companies expect a recovery in financial performance as elective surgeries resume to pre-COVID numbers.

According to the Centers for Disease Control and Prevention (CDC), approximately 26% (or 78 million) of American adults will suffer from arthritis by 2040. The prevalence increases with age and is more common in women. Obesity has been identified as another risk factor contributing to orthopedic conditions. The prevalence of obesity in the United States was estimated at 42.4% from 2017 to 2018 by the CDC. Rising prevalence of orthopedic diseases, obesity, and geriatric population is expected to fuel the growth of the market. Orthopedic regenerative surgical products find application in different conditions of varying severity, ranging from joint pain, gout, joint defects, fibromyalgia and osteoarthritis to trauma and joint replacements, which should help growth of the market.

Highlights of the Orthopedic Regenerative Surgical Products Market Report

  • Major factors driving the market include an aging population across the globe and an increase in the prevalence of orthopedic diseases. According to a 2019 review article published in the Elderly Health Journal, the prevalence of knee osteoarthritis in various Asian countries ranges from 13.1 to 71.1 percent.

  • The viscosupplement segment led the market and accounted for the largest revenue share of over 42.0% in 2021 owing to the increasing prevalence of osteoarthritis and associated symptoms and product availability.

  • Monovisc and Orthovisc by Anika Therapeutics have been the leading products in the viscosupplements market in the United States since 2018, based on combined global revenue.

  • In terms of application, the cartilage and tendon repair segment is estimated to experience the fastest CAGR of 4.1% due to increasing sports medicine applications, geriatric patients and case incidence. of trauma.

  • As most orthopedic procedures are performed in a hospital setting, the hospital segment held the largest revenue share of over 49.0% in 2021.

  • Drivers include a large number of populations affected by joint pain and other debilitating orthopedic conditions and support initiatives by governments and regulatory bodies. For example, October 12 has been proclaimed World Arthritis Day by Arthritis and Rheumatism International (ARI) to raise awareness of rheumatic and musculoskeletal diseases.

  • Market players are involved in the implementation of strategic initiatives, including R&D, product development and launches, regional expansion, and distribution network expansion.

Main topics covered:

Chapter 1 Methodology and Scope

Chapter 2 Executive Summary

Chapter 3 Orthopedic Regenerative Surgical Products Market Variables, Trends and Scope

Chapter 4 Orthopedic Regenerative Surgical Products Market: COVID-19 Impact Analysis

Chapter 5 Orthopedic Regenerative Surgical Products Market: Segment Analysis, by Product, 2017-2030 (USD Million)

Chapter 6 Orthopedic Regenerative Surgical Products Market Analysis, by Application, 2017-2030, (Revenue, Million USD)

Chapter 7 Orthopedic Regenerative Surgical Products Market: Segment Analysis, by End-Use, 2017-2030 (Million USD)

Chapter 8 Orthopedic Regenerative Surgical Products Market: Regional Market Analysis 2017-2030 (Million USD)

Chapter 9 Orthopedic Regenerative Surgical Products Market – Company Profiles

For more information about this report visit

See the source version on

Laura Wood, Senior Press Officer
[email protected]

For EST business hours, call 1-917-300-0470
For US/CAN call toll free 1-800-526-8630
For GMT office hours call +353-1-416-8900